The DAISY study and improved understanding of autoimmunity directed against insulin and novel methods to detect unknown pathogens (e.g. Skip Virgin: """"""""sentinel immunodeficient mice and representational difference analysis for newly acquired DNA and RNA) we believe provide unique opportunities to search for infectious agents potentially triggering the development of TIDM. We propose to pursue in parallel a general search for infectious pathogens and a focused project concentrating on a """"""""pathogenic"""""""" insulin peptide. Our preliminary data from the DAISY study indicates we can now identify children at birth (siblings of patients with type 1 diabetes with DR3/4, DQ8/2) with a risk of activating anti-islet autoantibody expression exceeding 50% within the first two years of life. In addition, we have recently discovered that given an appropriate genetic background (e.g. based on the MHC of Balb/c mice) we can readily induce anti-insulin autoantibodies with a specific insulin peptide in normal mice that is also recognized by human T cells. Using this peptide, combined with a viral mimic (poly-IC[polyinosinic-polycytodylic acid]) we can induce insulitis, and with a immunoregulatory defect in the islets (transgenic B7-1 expression), can induce islet destruction and diabetes. Development of diabetes in this model appears to be critically dependent upon genetic background, inducing environmental factors, and the """"""""coincidental"""""""" timing of inducing factors. This provides a model for """"""""environmental"""""""" induction of type 1 diabetes development and in the current proposal we will 1. Develop methodology and test intensive prospective evaluation of children for the appearance of anti-islet autoantibodies. 2. Detect the occurrence of infections (assays for inteferon alpha, 2',5'- oligoadenylate synthetase, """"""""sentinel immunodeficient mice"""""""", subtractive DNA and cDNA hybridization) and sequence environmental pathogens """"""""temporally"""""""" associated with appearance of anti-islet autoantibodies. 3. Define mimotopes of the B:9-23 peptide using """"""""random"""""""" peptide libraries and B:9-23 responsive T cell clones. 4. Test insulin, B:9-23 mimotopes, for the induction of insulin autoantibodies, insulitis, and diabetes in genetically susceptible murine strains. 5. Evaluate peptides of infectious pathogens with B:9-23 or mimotope related sequences for ability to stimulate B:9-23 reactive T cell clones of man and mouse. 6. Test pathogen related peptides that activate B:9-23 reactive T cell clones for disease induction in genetically susceptible murine strains and evaluate as in specific aim 1, whether specific pathogens with B:9-23/mimotope related sequences infect prediabetic children and the timing of appearance in children developing anti-islet autoimmunity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK062718-02
Application #
6622737
Study Section
Special Emphasis Panel (ZAI1-GLM-M (J1))
Program Officer
Akolkar, Beena
Project Start
2002-04-01
Project End
2006-01-31
Budget Start
2003-03-01
Budget End
2004-01-31
Support Year
2
Fiscal Year
2003
Total Cost
$152,334
Indirect Cost
Name
University of Colorado Denver
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Eisenbarth, George S (2010) Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 59:759-74
Babaya, Naru; Yu, Liping; Miao, Dongmei et al. (2009) Comparison of insulin autoantibody: polyethylene glycol and micro-IAA 1-day and 7-day assays. Diabetes Metab Res Rev 25:665-70
Baschal, Erin E; Eisenbarth, George S (2008) Extreme genetic risk for type 1A diabetes in the post-genome era. J Autoimmun 31:1-6
Zhang, Li; Nakayama, Maki; Eisenbarth, George S (2008) Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 20:111-8
Nakayama, Maki; Beilke, Joshua N; Jasinski, Jean M et al. (2007) Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 117:1835-43
Nakayama, M; Babaya, N; Miao, D et al. (2006) Long-term prevention of diabetes and marked suppression of insulin autoantibodies and insulitis in mice lacking native insulin B9-23 sequence. Ann N Y Acad Sci 1079:122-9
Babaya, N; Nakayama, M; Moriyama, H et al. (2006) A new model of insulin-deficient diabetes: male NOD mice with a single copy of Ins1 and no Ins2. Diabetologia 49:1222-8
Devendra, Devasenan; Miao, Dongmei; Nakayama, Maki et al. (2006) Pancreatic autoimmunity induction with insulin B:9-23 peptide and viral mimics in the NZB mouse. Ann N Y Acad Sci 1079:135-7
Jasinski, Jean M; Yu, Liping; Nakayama, Maki et al. (2006) Transgenic insulin (B:9-23) T-cell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Diabetes 55:1978-84
Gianani, R; Putnam, A; Still, T et al. (2006) Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies. J Clin Endocrinol Metab 91:1855-61

Showing the most recent 10 out of 34 publications